摘要
米拉贝隆是一种强效的选择性β_3受体激动剂,是治疗膀胱过度活动症(OAB)有效且耐受性良好的新型药物。临床研究证实,米拉贝隆可明显减少尿失禁次数、排尿次数并增加排尿量,在改善尿急发生和夜尿增多等方面也有很好的疗效,联合抗胆碱能药物后可提高疗效,但不增加药物不良反应发生率,为OAB提供了新的治疗手段,具有良好的应用前景。
As a powerful selective β_3 receptor agonist,mirabegron is an effective and well-tolerated new drug for the treatment of overactive bladder( OAB). Clinical studies have confirmed that mirabegron can significantly reduce the number of urinary incontinence and micturition frequency,increase the average voiding volume,and decrease the urgency feeling as well as the number of nocturia. Combined with anticholinergic drugs,mirabegron can improve curative effect without increasing the incidence of adverse drug reactions. Mirabegron provides a new treatment method for OAB with a good application prospect.
作者
种铁
陈琦
CHONG Tie, CHEN Qi(Department of Urology, the Second Affiliated Hospital of Xi'an Jiaotong University( Xibei Hospital), Xi'an 710004, Shaanxi, China)
出处
《山东大学学报(医学版)》
CAS
北大核心
2018年第3期6-11,共6页
Journal of Shandong University:Health Sciences